Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus.

Authors:
Morand EF; Abreu G; Furie RA; Golder V; Tummala R.

Journal:
Ann Rheum Dis

Publication Year: 2023

DOI:
10.1136/ard-2022-222748

PMCID:
PMC10176410

PMID:
36690388

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Ann Rheum Dis

Abbreviation: Ann Rheum Dis

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Rheumatology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Abatacept and non-melanoma skin cancer in patients with rheumatoid arthritis: a comprehensive evalu…
Simon TA; Dong L; Suissa S and 11 more (2024) - Transparency Score: 3/6
Correction: <i>Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 …
NA (2024) - Transparency Score: 1/6
Correction: <i>Identification of two tofacitinib subpopulations with different relative risk versus…
NA (2024) - Transparency Score: 1/6
Counteracting tryptophan metabolism alterations as a new therapeutic strategy for rheumatoid arthri…
Moulin D; Millard M; Taïeb M and 17 more (2024) - Transparency Score: 4/6
Data quality and patient characteristics in European ANCA-associated vasculitis registries: data re…
Gisslander K; Rutherford M; Aslett L and 24 more (2024) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
4/6
66.7% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Competing interests: EFM received grant support from AstraZeneca, Amgen, AbbVie, Biogen, Bristol Myers Squibb, Eli Lilly, EMD Serono, Genentech, GlaxoSmithKline (GSK), Janssen and UCB; received consulting fees from AstraZeneca, Amgen, Biogen, Bristol Myers Squibb, Eli Lilly, EMD Serono, Genentech, GSK, Janssen, Servier, UCB and Wolf Biotherapeutics; and has received speaking fees and/or honoraria from AstraZeneca, Eli Lilly, Novartis and GSK. RAF has received grant/research support and consulting fees from AstraZeneca. GA and RT are employees of and may hold stock in AstraZeneca."

Evidence found in paper:

"Funding: This study was funded by AstraZeneca."

Evidence found in paper:

"Trial registration numbers NCT02446912 and NCT02446899."

Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025